Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01532960 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer
A Phase 1 study, sponsored by Craig L Slingluff, Jr.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01532960 is a Phase 1 study that was terminated before completion, run by Craig L Slingluff, Jr. The registered enrollment target is 11 participants.
The verdict
NCT01532960, a Phase 1 study, was terminated before completion, sponsored by Craig L Slingluff, Jr.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Despite advances in surgical, radiation and medical therapies of early stage breast cancer, some patients will experience disease recurrence. Because recurrence may not happen for years after definitive treatment, there is a period of time between resection and relapse when micrometastatic disease may be amenable to immune eradication or modulation. While the ultimate goal of any cancer treatment is clinical efficacy, the immediate urgency in breast immunotherapy is to define treatments that have immunologic efficacy. In this study, the investigators will determine whether a vaccine consisting of nine-class I breast specific peptides plus a class II tetanus toxoid helper peptide is immunogenic when administered with poly-ICLC to participants with stage IB to IIIA breast cancer in the adjuvant setting.
Interventions
- BIOLOGICAL 9 Peptides from Her-2/neu, CEA, & CTA
- BIOLOGICAL poly-ICLC
- BIOLOGICAL Peptide-tet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2012-07 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01532960
The ClinicalTrials.gov registry entry for NCT01532960 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 9 Peptides from Her-2/neu, CEA, & CTA is the first listed.
NCT01532960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01532960 about?
NCT01532960 is a clinical study titled "Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer". Despite advances in surgical, radiation and medical therapies of early stage breast cancer, some patients will experience disease recurrence. Because recurrence may not happen for years after definitive treatment, there is a period of time between resection and relapse when micrometastatic disease m...
What is the current status of trial NCT01532960?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2012-07. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01532960?
The interventions under investigation include: 9 Peptides from Her-2/neu, CEA, & CTA (BIOLOGICAL), poly-ICLC (BIOLOGICAL), Peptide-tet (BIOLOGICAL).
Who is sponsoring clinical trial NCT01532960?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.